Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics Q1 revenue rises to $273 million; full-year product guidance raised

Mixed Impact 4 of 5 earnings Written later

PTC Therapeutics reported first quarter 2026 total revenue of $272.6 million and a net loss of $2.8 million, or $0.03 per share, compared with net income of $866.6 million a year earlier. The year-earlier figure included $986.2 million of collaboration and license revenue, while net product revenue rose 47% to $225.6 million. The company raised its full-year 2026 product revenue guidance to $750 million to $850 million.

Key points

  • Total revenue was $272.6 million in Q1 2026, versus $1,176.1 million in Q1 2025, which included $986.2 million of collaboration and license revenue.
  • Net product revenue was $225.6 million, up 47% from $153.4 million a year earlier; Sephience revenue was $124.6 million.
  • Net loss was $2.8 million, or $0.03 per share, compared with net income of $866.6 million in Q1 2025.
  • Full-year 2026 total product revenue guidance was raised to $750 million to $850 million, with expected total revenue of $1.08 billion to $1.18 billion; GAAP R&D and SG&A expense guidance was unchanged at $775 million to $815 million.

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECMay 7, 2026, 4:09 PM ET
Accession number0001070081-26-000011

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.